ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK, Warp Drive form library alliance

by Michael McCoy
April 3, 2017 | APPEARED IN VOLUME 95, ISSUE 14

GlaxoSmithKline and Warp Drive Bio are joining small-molecule generation technologies to create a library of up to 200 million compounds. The alliance combines Warp Drive’s Small Molecule-Assisted Receptor Targeting platform with GSK’s Encoded Library Technology to create compounds targeting disease-causing proteins previously considered to be intractable. Each company will independently develop and commercialize drugs against its respective targets.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment